Merck raises revenue outlook to $67.3 billion, cuts profit guidance due to losses

Merck reported a net loss of $1.34 billion for the second quarter of 2023, prompting the pharmaceutical giant to cut its profit outlook while raising its revenue projections. The company announced these results on Tuesday, highlighting strong sales from new products but facing significant charges related to its recent acquisitions.

The upward revision of Merck's revenue forecast is notable, with the company now projecting 2026 revenue between $66.3 billion and $67.3 billion. This is an increase from the previous estimate of $65.8 billion to $67 billion. However, the profit guidance was lowered due to a $5.7 billion charge associated with the acquisition of Terns Pharmaceuticals and a $9 billion charge from its earlier purchase of Cidara Therapeutics. Adjusted earnings per share are now expected to be between $2.66 and $2.76, a sharp decline from the earlier range of $5.04 to $5.16.

Despite the loss, Merck's revenue for the quarter reached $16.61 billion, marking a 5% increase from last year. The company's blockbuster drug Keytruda generated $8.37 billion in sales, exceeding analyst expectations. The new injectable version of Keytruda contributed $463 million, reflecting Merck's strategy to adapt as the original version faces patent expiration. Other new products, including Winrevair, which treats a rare lung condition, saw impressive growth, bringing in $588 million, while the pneumococcal vaccine Capvaxive added $184 million to sales.

Looking ahead, Merck is focused on expanding its portfolio to mitigate revenue losses from upcoming generic competition. The company is banking on new products to fill the gap left by established drugs like Januvia and Janumet, which face generic versions later this year. This shift in strategy underlines Merck's determination to remain competitive in a rapidly changing pharmaceutical landscape.